Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InSightec ExAblate Panel To Consider International Uterine Fibroid Data

This article was originally published in The Gray Sheet

Executive Summary

InSightec's PMA for non-invasive ExAblate 2000 treatment of uterine fibroids will be reviewed by FDA's Obstetrics & Gynecology Devices Panel June 3

You may also be interested in...



InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required

FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission

InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required

FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission

InSightec Panel Acquiesces Despite Efficacy, Control Group Concerns

Labeling for InSightec's ExAblate 2000 non-invasive uterine fibroid treatment should describe "mitigations" to minimize the risk of nerve damage during the procedure, FDA advisory panel members recommend

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel